Designing phase II trials in cancer: A systematic review and guidance

British Journal of Cancer

Volumn 105, Issue 2, 2011, Pages 194-199

  Brown, S R ^a   Gregory, W M ^a   Twelves, C J ^b   Buyse, M ^c   Collinson, F ^a,b   Parmar, M ^d   Seymour, M T ^b   Brown, J M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

guidance manual; methodology; phase II; systematic review; trial design

Indexed keywords

CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; DATA EXTRACTION; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; METHODOLOGY; NEOPLASM; ONCOLOGY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STATISTICAL ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC);

ALGORITHMS; CLINICAL TRIALS, PHASE II AS TOPIC; GUIDELINES AS TOPIC; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 79960239432     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.235     Document Type: Review

References (23)

1. Adjei AA, Christian M, Ivy P (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866-1872
2. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK (2008) Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 44: 25-29 (Pubitemid 350256934)
3. Brown SR, Gregory WM, Twelves C, Buyse M, Parmar M, Seymour MT, Brown J (2011) A practical guide to facilitate the clinician/statistician interface in designing phase II oncology trials. Unpublished work
4. Buyse M (2000) Randomized designs for early trials of new cancer treatments-an overview. Drug Inf J 34: 387-396 (Pubitemid 30350991)
5. Collier R (2009) Drug development cost estimates hard to swallow. Can Med Assoc J 180(3): 279-280
6. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15: 1873-1882
7. DiMasi JA, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25: 209-216 (Pubitemid 350003036)
8. Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D (2010) Randomized phase II trials: inevitable or inadvisable? J Clin Oncol 28: 2641-2647
9. Karrison TG, Maitland ML, Stadler WM, Ratain MJ (2007) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99: 1455-1461
10. Lee JJ, Feng L (2005) Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 23: 4450-4457 (Pubitemid 46209969)
11. Machin D, Campbell MJ (2005) Design of Studies for Medical Research. John Wiley & Sons: Chichester
12. Machin D, Campbell MJ, Tan S-B, Tan S-H (2009) Sample Size Tables for Clinical Studies. Wiley-Blackwell: Chichester
13. Mariani L, Marubini E (1996) Design and analysis of phase II cancer trials: A review of statistical methods and guidelines for medical researchers. Int Stat Rev 64: 61-88
14. Mariani L, Marubini E (2000) Content and quality of currently published phase II cancer trials. J Clin Oncol 18: 429
15. McShane LM, Hunsberger S, Adjei AA (2009) Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 15: 1898-1905
16. Perrone F, Di Maio M, De Maio E, Maione P, Ottaiano A, Pensabene M, Di Lorenzo G, Lombardi AV, Signoriello G, Gallo C (2003) Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncol 4: 305-311 (Pubitemid 36592498)
17. Redman M, Crowley J (2007) Small randomized trials. J Thorac Oncol 2: 1-2 (Pubitemid 47163920)
18. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D (2009) Randomized phase II designs. Clin Cancer Res 15: 1883-1890
19. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D (2010) The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 16: 1764-1769
20. Stewart DJ (2010) Randomized phase II trials: misleading and unreliable. J Clin Oncol 28: e649-e650
21. Thezenas S, Duffour J, Culine S, Kramar A (2004) Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer 40: 1244-1249 (Pubitemid 38526344)
22. Walker I, Newell H (2009) Do molecularly targeted agents in oncology have reduced attrition rateS Nat Rev Drug Discov 8: 15-16
23. Yothers G, Wieand HS, Freireich EJ (2006) Pro/Con: Randomization in phase II clinical trials. Clin Adv Hematol Oncol 4: 776-778 (Pubitemid 44794708)